Christopher Hall | Senior Research Assistant

Hall, Christopher

I am part of the flow cytometry core facility team and my primary responsibilities are to run the flow cytometer sorters, maintain the flow cytometer analysers and to provide technical and scientific expertise to our users. I work closely with the Single Cell Genomics team as we provide them with the single cells used in their facility. I have produced a range of Python and R scripts to automate many common tasks in the facility (https://github.com/SangerCytometry). My previous immunology and microbiology experience and work as multirole lab technician allows me to bring a wide range of skills and knowledge to the flow core.

Previously I worked with Dr Valerie Corrigall at KCL on the Rasolvir phase I/IIa clinical trial. My primary responsibly was to process and analyse patient blood samples using flow cytometry, qPCR, multiplex & traditional ELISAs and by conducting cell proliferation experiments.

Before this I worked at GSK: Barnard Castle as a QA microbiology technician monitoring for microbial contamination in drug products or in the factory environment.

My first job was at Findus UK Ltd. in Newcastle (the world’s largest pancake factory). Here I was a microbiology technician monitoring for microbial contamination in food products or in the factory environment.

In my spare time I enjoy running, building things and watching football (Newcastle United). I am also an active member of CAMRA (Herts and Essex Borders). This year I plan to learn to fly (an aeroplane) and learn a language (I try this every year, which is why I know a little bit of French, Spanish, German, Dutch and Russian, but cannot converse in any).

Publications

  • Inflammatory cytokines compromise programmed cell death-1 (PD-1)-mediated T cell suppression in inflammatory arthritis through up-regulation of soluble PD-1.

    Bommarito D, Hall C, Taams LS and Corrigall VM

    Clinical and experimental immunology 2017;188;3;455-466

  • Safety and patient response as indicated by biomarker changes to binding immunoglobulin protein in the phase I/IIA RAGULA clinical trial in rheumatoid arthritis.

    Kirkham B, Chaabo K, Hall C, Garrood T, Mant T et al.

    Rheumatology (Oxford, England) 2016;55;11;1993-2000

  • Defective CD8+CD28+ regulatory T cell suppressor function in rheumatoid arthritis is restored by tumour necrosis factor inhibitor therapy.

    Ceeraz S, Hall C, Choy EH, Spencer J and Corrigall VM

    Clinical and experimental immunology 2013;174;1;18-26

Hall, Christopher
Christopher's Timeline
2015

Began work at the Wellcome Trust Sanger Institute Cytometry Core Facility

2011

Started work on the BiP (RAsolvir) clinical trial

2009

Attained a MSc in Cancer Immunotherapy at Nottingham Univeristy

2004

Completed BSc(Hons) in Applied Biology at Newcastle University